Glutamate Carboxypeptidase II
"Glutamate Carboxypeptidase II" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A metallocarboxypeptidase that is predominantly expressed as a membrane-bound enzyme. It catalyzes the hydrolysis of an unsubstituted, C-terminal glutamyl residue, typically from PTEROYLPOLYGLUTAMIC ACIDS. It was formerly classified as EC 3.4.19.8.
| Descriptor ID |
D043425
|
| MeSH Number(s) |
D08.811.277.656.350.245.400 D08.811.277.656.350.555.500 D08.811.277.656.675.555.500
|
| Concept/Terms |
Glutamate Carboxypeptidase II- Glutamate Carboxypeptidase II
- Carboxypeptidase II, Glutamate
- FOLH1 Protein
- N-Acetylaspartylglutamate Peptidase
- N Acetylaspartylglutamate Peptidase
- Peptidase, N-Acetylaspartylglutamate
- NAALADase L
- NAAG Peptidase
- NAALADase
- NAALADase II
- Folate Hydrolase I
- Hydrolase I, Folate
- N-Acetylated-alpha-Linked Acidic Dipeptidase
- Acidic Dipeptidase, N-Acetylated-alpha-Linked
- Dipeptidase, N-Acetylated-alpha-Linked Acidic
- N Acetylated alpha Linked Acidic Dipeptidase
|
Below are MeSH descriptors whose meaning is more general than "Glutamate Carboxypeptidase II".
Below are MeSH descriptors whose meaning is more specific than "Glutamate Carboxypeptidase II".
This graph shows the total number of publications written about "Glutamate Carboxypeptidase II" by people in this website by year, and whether "Glutamate Carboxypeptidase II" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2017 | 9 | 3 | 12 |
| 2018 | 1 | 2 | 3 |
| 2019 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Glutamate Carboxypeptidase II" by people in Profiles.
-
Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography in Men with Nonmetastatic Castration-Resistant Prostate Cancer. Clin Cancer Res. 2019 12 15; 25(24):7448-7454.
-
EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands (177Lu-PSMA-RLT). Eur J Nucl Med Mol Imaging. 2019 Nov; 46(12):2536-2544.
-
Theranostics for Advanced Prostate Cancer: Current Indications and Future Developments. Eur Urol Oncol. 2019 03; 2(2):152-162.
-
Positive effect of Actinium 225-PSMA treatment on ECOG performance status: A case report on a patient with castration resistant stage IV prostate carcinoma. Rev Esp Med Nucl Imagen Mol (Engl Ed). 2019 Jul - Aug; 38(4):260-261.
-
Passive-specific immunotherapy with monoclonal antibodies for prostate cancer: A systematic review. J Oncol Pharm Pract. 2019 Jun; 25(4):903-917.
-
The role of 68Ga-PSMA PET/CT scan in biochemical recurrence after primary treatment for prostate cancer: a systematic review of the literature. Minerva Urol Nefrol. 2018 Oct; 70(5):462-478.
-
A Prospective Comparison of 18F-Sodium Fluoride PET/CT and PSMA-Targeted 18F-DCFBC PET/CT in Metastatic Prostate Cancer. J Nucl Med. 2018 11; 59(11):1665-1671.
-
Androgen receptor overexpression in prostate cancer in type 2 diabetes. Mol Metab. 2018 02; 8:158-166.
-
Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors. J Nucl Med. 2018 03; 59(3):494-501.
-
Prostate Cancer Molecular Imaging Standardized Evaluation (PROMISE): Proposed miTNM Classification for the Interpretation of PSMA-Ligand PET/CT. J Nucl Med. 2018 03; 59(3):469-478.